Drug major Cipla Ltd has reported a jump of over two-fold in its consolidated net profit after taxes (PAT) at Rs 650.61 crore for the first quarter ended June 30, 2015, led by robust sales.
"The consolidated net profit of the company stood at Rs 294.58 crore during the same period a year ago," said Cipla Ltd in a filing to the Bombay Stock Exchange.
Further, the consolidated total income of the pharma major increased by 41.3 per cent at Rs 3,901.7 crore during Q1 FY16, as compared to Rs 2,760.39 crore during the same period last year.
It's net sales increased to Rs 3,776.82 crore compared with Rs 2,647.20 crore reported a year back.
"The results for the current period includes one-off revenue from the US market," Cipla said without specifying the details.
On domestic front, its sales grew by 8.4 per cent to Rs 1,397 cr during Q1 FY1516, up from Rs 1,289 cr during Q1 FY1415, mainly on account of growth in Respiratory, Anti-infectives, Cardiac and Gastro Intestinal therapies.
Globally, company's exports of formulations increased by 78.5 per cent to Rs 2,174 cr during Q1 FY1516, from Rs 1,218 cr during Q1 FY1415. Exports of APIs increased by 47 per cent at Rs 206 cr during Q1 FY1516, from Rs 140 cr during Q1 FY1415.
The outlook for FY16 remains strong with the company expecting a 20 per cent topline growth in the fiscal year. It is also evaluating reinvestment options in R&D, Consumer Healthcare and Biologics, Cipla said.
Meanwhile, shares of the company ended Friday's trade at Rs 740.50 apiece, up 2.06 per cent, from previous close on BSE.